Trial reportESMO open2025
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.
Trial report in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04494425 (A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Who cites it
8 citing papers in PubMed.
- Emerging role of human epidermal growth factor 2-low status in the prognosis and management of triple-negative breast cancer: a narrative review.Translational cancer research · 2026Review
- Advances in Pharmacologic- and Non-pharmacologic Interventions for Cancer Pain: A Narrative Review.Current treatment options in oncology · 2026Review
- Targeted therapies in pediatric oncology: A start.Molecular therapy. Oncology · 2026Review
- Mapping adverse events and monitoring priorities for trastuzumab deruxtecan use in metastatic breast cancer.International journal of surgery (London, England) · 2026Article
- Trastuzumab deruxtecan in advanced breast cancer: a real-world study of efficacy and safety in Chinese cohort with HER2-positive and HER2-low expression.Frontiers in oncology · 2026Article
- Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens.Pharmaceutics · 2025Review
- Quantification of HER2-low and ultra-low expression in breast cancer specimens by quantitative IHC and artificial intelligence.Journal of pathology informatics · 2025Article
- Disproportionality Analysis of Gastrointestinal Adverse Events Associated With Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report database.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe randomized phase III DESTINY-Breast06 trial (NCT04494425) demonstrated superior efficacy with trastuzumab deruxtecan (T-DXd) versus chemotherapy treatment of physician's choice (TPC) and no new safety signals in patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-low [immunohistochemistry (IHC) 1+, IHC 2+/in situ hybridization-negative], and HER2-ultralow (IHC 0 with membrane staining) metastatic breast cancer (mBC). Here, we report the patient-reported outcome (PRO) endpoints in the intent-to-treat (ITT; HER2-low/-ultralow) and HER2-low populations. PATIENTS AND
methodsPatients with progressive disease (PD) after one or more prior lines of endocrine-based therapy and no prior chemotherapy for mBC were assigned 1 : 1 to T-DXd 5.4 mg/kg once every 3 weeks (n = 436) or TPC [n = 430; 59.8% capecitabine; 24.4% nab-paclitaxel; and 15.8% paclitaxel]. PRO questionnaires included the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and breast cancer-specific module (EORTC QLQ-BR45). Changes from baseline (CFB; earliest of 31 weeks or on-study PD) and time to deterioration were assessed.
resultsThe median treatment duration was 11.0 (T-DXd) versus 5.6 (TPC) months. In the ITT, the mean CFB scores were similar across treatments in EORTC QLQ-C30 global health status/quality of life (QOL) and functioning scales. T-DXd was associated with less pain [adjusted mean difference -7.2, 95% confidence interval (CI) -9.9 to -4.5] and fewer skin/mucosal symptoms (adjusted mean difference -9.5, 95% CI -11.5 to -7.5), but more nausea/vomiting (adjusted mean difference 7.2, 95% CI 5.3-9.2), appetite loss (adjusted mean difference 6.8, 95% CI 3.6-10.0), and constipation (adjusted mean difference 5.5, 95% CI 2.6-8.4) versus TPC. T-DXd reduced the risk of clinically meaningful deterioration in physical/role/emotional functioning, pain, and fatigue versus TPC, but increased the risk of deterioration in gastrointestinal symptoms. Results were similar in the HER2-low population.
conclusionsT-DXd preserved QOL while delaying deterioration in physical/role/emotional functioning, pain, and fatigue versus TPC, albeit with more gastrointestinal symptoms. PRO data complement the efficacy/safety of T-DXd in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.